{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218134","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2026-05-12T11:00:16+00:00","discovered_at":"2026-05-12T11:05:00.252128+00:00","generated_at":"2026-05-12T11:17:31.820315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026","bullets":["Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.","R&D expenses $3.5M, G&A $2.1M; other income $10.6M from fair value adjustments on warrants and note.","FDA feedback on pivotal program design for Auxora in acute pancreatitis expected in Q2 2026.","IND submission for oral CRAC inhibitor CM5480 in pulmonary hypertension anticipated in 2027.","Phase 2b CARPO results published: Auxora showed 100% reduction in new-onset severe respiratory failure (p<0.05)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218134","json":"https://secwatch.observer/filing/0001193125-26-218134.json","markdown":"https://secwatch.observer/filing/0001193125-26-218134.md","text":"https://secwatch.observer/filing/0001193125-26-218134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/0001193125-26-218134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:17:31.820315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13c6694fd9fdcaa0a8a3a76f7d429410232750bc","claim":"CalciMedica, Inc. reported first quarter ended March 31, 2026 results: net income Net income was $5.0 million, EPS $0.31 per basic share and $0.30 per diluted share.","evidence_excerpt":"Net income was $5.0 million, or $0.31 per basic share and $0.30 per diluted share, for the three months ended March 31, 2026, compared to a net loss of $5.0 million, or $0.36 per basic","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/0001193125-26-218134-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net income was $5.0 million"},{"label":"EPS","value":"$0.31 per basic share and $0.30 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}